| Literature DB >> 26193270 |
Chenze Zhang1, Wenqiang Yan2, Bi Li3, Bing Xu4, Yan Gong5, Fuhao Chu6, Yuzhong Zhang7, Qiuli Yao8, Penglong Wang9, Haimin Lei10.
Abstract
A new anticancer ligustrazine derivative, 3β-hydroxyolea-12-en-28-oic acid- 3,5,6-trimethylpyrazin-2-methylester (T-OA, C38H58O3N2), was previously reported. It was synthesized via conjugating hepatoprotective and anticancer ingredients of traditional Chinese medicine. We found that T-OA exerted its anticancer activity by preventing the expression of nuclear transcription factor NF-κB/p65 and COX-2 in S180 mice. However, the selective cytotoxicity of T-OA on various kinds of cell lines has not been studied sufficiently. In the present study, compared with Cisplatin, T-OA was more toxic to human hepatoma cell line Bel-7402 (IC50 = 6.36 ± 1.56 µM) than other three cancer cell lines (HeLa, HT-29, BGC-823), and no toxicity was observed toward Madin-Darby canine kidney cell line MDCK (IC50 > 150 µM). The morphological changes of Bel-7402 cells demonstrated that T-OA had an apoptosis-inducing effect which had been substantiated using 4',6-diamidino-2-phenylindole (DAPI) staining, acridine orange (AO)/ethidium bromide (EB) staining, flow cytometry and mitochondrial membrane potential assay. Combining the immumohistochemical staining, we found T-OA could prevent the expression of NF-κB/p65 and COX-2 in Bel-7402 cells. Both of the proteins have been known to play roles in apoptosis and are mainly located in the nuclei. Moreover subcellular localization was performed to reveal that T-OA exerts in nuclei of Bel-7402 cells. The result was in accordance with the effects of down-regulating the expression of NF-κB/p65 and COX-2.Entities:
Keywords: NF-κB/p65 and COX-2; hepatoma; ligustrazine derivative; selective cytotoxicity
Mesh:
Substances:
Year: 2015 PMID: 26193270 PMCID: PMC4519956 DOI: 10.3390/ijms160716401
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Structure of T-OA.
IC50 values (µM) of T-OA and Cisplatin on different cell lines.
| Compound | IC50 Values (µM) | ||||
|---|---|---|---|---|---|
| Bel-7402 | HeLa | HT-29 | BGC-823 | MDCK | |
| T-OA | 6.36 ± 1.56 | 28.73 ± 5.89 | 29.84 ± 6.73 | >30 | >150 |
| Cisplatin | 5.94 ± 1.48 | 6.22 ± 2.06 | 6.11 ± 2.31 | 6.82 ± 1.79 | 3.70 ± 2.89 |
Figure 2Selective cytotoxicity of T-OA on Bel-7402 and MDCK cell lines.
Figure 3Morphological changes of Bel-7402 cells assessed by Giemsa staining. (a) Control group without T-OA; (b) Treated with 5 µM T-OA; (c) Treated with 10 µM T-OA; and (d) Treated with 20 µM T-OA. (×400).
Figure 4DAPI (I) and acridine orange/ethidium bromide (AO/EB) (II) staining of the Bel-7402 cells treated by T-OA. (Ia) Control group without T-OA; (Ib) Treated with 5 µM T-OA; (Ic) Treated with 10 µM T-OA; (Id) Treated with 20 µM T-OA; (IIa) Control group without T-OA; (IIb) Treated with 5 µM T-OA; (IIc) Treated with 10 µM T-OA; (IId) Treated with 20 µM T-OA. (×200).
Figure 5Apoptosis ratio detection by Annexin V/PI assay on the Bel-7402 cells treated by T-OA. (a) Control group without T-OA; (b) Treated with 5 µM T-OA; (c) Treated with 10 µM T-OA; (d) Treated with 20 µM T-OA.
Figure 6Mitochondrial membrane potential detection by Rhodamine 123 staining on the Bel-7402 cells treated by T-OA. (a) Control group without T-OA; (b) Treated with 5 µM T-OA; (c) Treated with 10 µM T-OA; and (d) Treated with 20 µM T-OA.
Figure 7Immunohistochemical analysis of NF-κB/p65 (I) and COX-2 (II) in control and T-OA treated groups of Bel-7402 cells. (Ia) Control group without T-OA; (Ib) Treated with 5 µM T-OA; (Ic) Treated with 10 µM T-OA; (Id) Treated with 20 µM T-OA; (IIa) Control group without T-OA; (IIb) Treated with 5 µM T-OA; (IIc) Treated with 10 µM T-OA; and (IId) Treated with 20 µM T-OA. (×400).
Figure 8Subcellular localization of T-OA in Bel-7402 cells. (a) Control group at 488 nm; (b) Control group at 514 nm; (c) Merged image of control group; (d) T-OA fluorescent analogue treated group at 488 nm; (e) T-OA fluorescent analogue treated group at 514 nm; and (f) Merged image of T-OA fluorescent analogue treated group. (×600).